Important pharmacy news and late-breaking industry information updated daily.
FDA issued on Thursday a warning letter to CanaRx, a Canadian drug distributor, for facilitating the distribution of unapproved new drugs and misbranded drugs to Americans.
After about 5 years of large declines, the number of HIV infections in the United States started to plateau in 2013, at about 39,000 infections a year, CDC reported Wednesday. The agency's analysis looked at HIV trends in the United States from 2010 to 2016.
FDA Commissioner Scott Gottlieb outlined on Tuesday the steps his agency is taking this year to fight the opioid epidemic.
A new research paper published online February 19 in the Journal of the American Pharmacists Association may provide pharmacists with some clues on how to successfully integrate into a primary care physician practice.
Pharmaceutical industry executives will face questioning Tuesday at a Senate hearing on the rising cost of medicines. Scheduled to testify before the Senate Finance Committee are CEOs from AbbVie, Bristol-Myers Squibb, Merck, Pfizer, AstraZeneca, and Sanofi. Johnson & Johnson is sending an executive who oversees its drug division.
FDA is tightening up rules to make OTC sunscreen products more safe and effective. On February 21, FDA announced a proposed rule that would update regulatory requirements for sunscreens sold in the United States.
Sen. Chuck Grassley (R-IA), chairman of the Senate Finance Committee, and Sen. Ron Wyden (D-OR), the committee's top Democrat, on Friday sent letters to the heads of Eli Lilly, Novo Nordisk, and Sanofi, the leading manufacturers of insulin, seeking answers as to why the drug's cost has rapidly risen.
Mark your calendar: CDC’s Division for Heart Disease and Stroke Prevention (DHDSP) will host “Let’s Talk About Cholesterol: Facebook Live Cholesterol Experts’ Panel,” on Monday, February 25, at 12:30 PM ET. Access the event at facebook.com/millionhearts.
Statins are an effective, low-cost therapy for reducing cardiovascular risk, yet they remain one of the most controversial classes of drugs. A new scientific statement from the American Heart Association (AHA) aims to clear up some of the known and perceived risks of statins by providing clinicians with an evidence-based breakdown of the various adverse effects and concerns linked with statin therapy.
Janet Woodcock, MD, director of FDA's Center for Drug Evaluation and Research, reports the agency is continuing an investigation and recall of a class of drugs used by millions that began last summer. Starting in July, separate lots of blood pressure medications from various companies were pulled from pharmacy shelves.